Fluidigm Focusing on Partnerships as IPO Remains Goal | GenomeWeb

By Edward Winnick

NEW YORK (GenomeWeb News) - Fluidigm officials said Monday that the firm is focusing on growing its business and inking partnerships as it keeps its eye on a potential initial public offering.

The microfluidics and array manufacturer was forced to withdraw its proposed IPO amid the market meltdown a year ago. At the time, company officials said that Fluidigm would go public once the markets stabilized.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: molecular surveillance of S. Typhi, genome-wide association study of attention in children, and more.

Clinicians look to fold non-medical data into algorithms to predict patients' health, the Wall Street Journal reports.

Connecticut's biotech investment is leading to the building of labs to house new startups, the Associated Press reports.

Craig Venter's Health Nucleus aims to change preventive medicine, according to the Robb Report.